Intravenous esomeprazole 40 mg vs. intravenous lansoprazole 30 mg for controlling intragastric acidity in healthy adults
| Autor: | Joseph R. Pisegna, Mark Sostek, John T. Monyak, Philip B. Miner |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Gastric Acidity Determination
medicine.medical_specialty Hepatology biology business.industry medicine.drug_class Gastroenterology Lansoprazole Proton-pump inhibitor Pharmacology biology.organism_classification Crossover study law.invention Esomeprazole Randomized controlled trial law Internal medicine Medicine Pharmacology (medical) Helicobacter Dosing business medicine.drug |
| Zdroj: | Alimentary Pharmacology & Therapeutics. 27:483-490 |
| ISSN: | 1365-2036 0269-2813 |
| DOI: | 10.1111/j.1365-2036.2007.03592.x |
| Popis: | Summary Background Intravenous (IV) formulations of proton pump inhibitors are effective for patients in whom oral therapy is not appropriate. Aim To compare IV esomeprazole and IV lansoprazole for the control of intragastric pH. Methods In this open-label crossover study, healthy, Helicobacter pylori-negative adults were randomized to one of two treatment sequences, each consisting of two 5-day dosing periods of IV esomeprazole 40 mg or IV lansoprazole 30 mg. Twenty-four-hour intragastric pH monitoring was conducted on days 1 and 5 of each dosing period. Results On days 1 and 5, intragastric pH was >4.0 significantly longer with esomeprazole than lansoprazole (least-squares means: day 1, 40.0% vs. 33.6%; day 5, 61.9% vs. 45.4%; both P 4.0 significantly longer on days 1 and 5 with esomeprazole than lansoprazole (P 4.0 were 4.92 for esomeprazole and 5.75 for lansoprazole (P = 0.0014 for test on Gehan scores). Conclusion In healthy adults, IV esomeprazole 40 mg controlled intragastric acidity faster and more effectively than IV lansoprazole 30 mg. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text